Quhill, F., and A. Beiderbeck. “Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) Versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema”. Global and Regional Health Technology Assessment, vol. 4, no. 1, July 2017, pp. 155-64, doi:10.33393/grhta.2017.391.